Emergency / crisis support: /emergency
Allergic rhinitis does not typically produce medical emergencies or large financial crises. However, anaphylaxis during SCIT, immunotherapy funding disputes, and intranasal medication access issues are the specific crisis points for this condition.
Anaphylaxis During Subcutaneous Immunotherapy (SCIT): Emergency
SCIT (allergy injection) carries a small but real risk of systemic allergic reaction (anaphylaxis), which is why all injections are administered in a clinic with a mandatory 30-minute post-injection observation period and adrenaline immediately available.
If an anaphylactic reaction occurs: - You are already in a clinical setting — allergy clinic staff are trained to respond immediately with adrenaline (epinephrine), antihistamines, and IV access. - Anaphylaxis is a PMB emergency. Emergency treatment of anaphylaxis is PMB-covered regardless of the underlying reason. - Do NOT administer SCIT injections outside of a clinical setting or without post-injection observation. This is a safety requirement, not a preference.
If you carry an EpiPen (prescribed as a precaution for severe atopic disease), ensure it is accessible at all times and the prescription is kept current.
Common Allergic Rhinitis Financial Issues
- Immunotherapy declined or not covered by scheme
- Intranasal corticosteroid not on formulary
- MSA depleted — ongoing medications need funding
- Diagnostic testing (SPT/RAST) charged against wrong benefit
If Immunotherapy Was Declined
Allergen-specific immunotherapy is well-evidenced as disease-modifying (ARIA guidelines, EAACI immunotherapy guidelines). A scheme that declines SCIT or SLIT for documented moderate-to-severe allergic rhinitis refractory to medical therapy can be challenged.
For SCIT: Your allergist should submit an exceptional-needs motivation with: specific allergen sensitisation documented by SPT or RAST, symptom severity and impact, failure of conventional medical therapy (nasal steroids + antihistamines at adequate duration), and guideline reference for immunotherapy in persistent moderate-severe allergic rhinitis.
If SCIT is declined, ask whether SLIT is covered — some schemes that decline SCIT approve SLIT due to lower cost and lower risk profile.
If both are declined: immunotherapy in SA can be self-funded at R800–R2,000/month. This is a significant cost over a 3–5 year course (R30,000–R100,000 total) but produces long-term disease modification that reduces ongoing medication costs and improves quality of life. Discuss the cost-benefit with your allergist.
If Intranasal Corticosteroid Is Not Funded
Intranasal corticosteroids are inexpensive prescription medications. If declined on formulary grounds: - Ask your prescriber to switch to an alternative that is on the formulary (most schemes cover at least one intranasal steroid brand) - Generic fluticasone or mometasone preparations are available at significantly lower cost — ask for the generic
If no intranasal steroid is covered at all, the annual self-funded cost is approximately R1,800–R3,000 — low enough that self-funding is practical for many patients.
If Diagnostic Tests Were Mis-Billed
Skin prick testing (SPT) is sometimes incorrectly billed as a procedure under a consultation rather than a separate diagnostic test, or vice versa — causing a benefit category mismatch and unexpected out-of-pocket cost.
Request an itemised account from the allergist's rooms and compare the billing codes with the scheme's explanation of benefits. If SPT or RAST was applied against the wrong benefit category, request reprocessing with the corrected code.
Triage Table
| Situation | Priority | Action |
|---|---|---|
| Anaphylaxis during SCIT | Emergency | Clinical staff respond; epinephrine; PMB emergency |
| Immunotherapy declined | Medium | Enhanced exceptional-needs motivation; consider SLIT alternative |
| Intranasal steroid not funded | Low | Formulary alternative; generic switch; self-fund (low cost) |
| Diagnostic tests mis-billed | Low | Reprocessing request with corrected codes |
| MSA depleted — antihistamines needed | Low | OTC purchase; cetirizine/loratadine very inexpensive |
Escalation Contacts
Council for Medical Schemes (CMS): 0861 123 267 | www.medicalschemes.org.za Allergy Society of South Africa (ALLSA): www.allergysociety.co.za AURA Emergency: /emergency
Talk to Eldon
Get urgent help with your cover situation →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
When Symptoms Are Not Allergic Rhinitis
Some conditions that mimic allergic rhinitis require different management and different coverage pathways:
Chronic rhinosinusitis with nasal polyps (CRSwNP): Presents with nasal obstruction, loss of smell, and thick mucus. Nasal polyps seen on endoscopy or CT. This is a separate ICD-10 condition (J33) with distinct management — including dupilumab biologics for severe refractory disease. If your rhinitis is not responding and you have prominent loss of smell, request an ENT referral and endoscopic assessment.
Non-allergic rhinitis (vasomotor rhinitis): Rhinitis triggered by temperature changes, strong smells, or exercise rather than allergens. Negative allergy tests. Managed similarly to allergic rhinitis but immunotherapy is not effective because there is no allergen to desensitise against. Coverage profile is the same as allergic rhinitis.
Occupational rhinitis: Rhinitis triggered by workplace allergens or irritants. If symptoms correlate with work attendance and improve on weekends or holidays, occupational exposure may be the primary driver. Occupational health assessment is the appropriate pathway.
These distinctions matter because the coverage pathway differs — particularly for CRSwNP where dupilumab biologic therapy (and the associated exceptional-needs pathway) may be applicable.
Seasonal Planning: Getting Prescriptions Right
For seasonal allergic rhinitis (grass pollen season in SA: typically September–December in most regions), prepare in advance:
- Obtain intranasal steroid and antihistamine prescriptions before peak season starts — commencing intranasal steroid 2 weeks before season onset produces better symptom control than starting reactively
- Ensure sufficient medication quantity is dispensed — avoid running short during peak season when symptoms are worst
- Pre-authorise any allergy specialist appointments before the season if possible, given clinic waiting times during peak allergy months